Translating London scientific excellence into global therapeutic strategies

Event Date:
Tuesday 10th September 2019 at 08:00
British Residence Boston
View ProgramView Program

A Department of International Trade - Life Sciences Event

The event will focus on innovative early drug development opportunities in London, the South East and the broader United Kingdom

With support from the British Embassy in Boston and New York, Richmond Pharmacology will be holding an event to showcase how London’s unique Life sciences environment can support sustainable and optimised global drug development.

To confirm your attendance please RSVP

First Speakers Confirmed

Dr Martin O'Kane MRPharmS

Head of Clinical Trials, Medicines and Healthcare products Regulatory Agency (MHRA)Dr Martin O'Kane is a pharmacist by training with a PhD in neuropharmacology and post-doctorate research experience in neuroscience. Following a period in Japan working within the pharmaceutical industry, he joined the MHRA working for the British Pharmacopoeia and was a member of the European Pharmacopoeia Commission’s Working Party on Cell Therapy Products. He moved to the Clinical Trials Unit as a Pharmaceutical Assessor in 2007 and has been involved in the assessment of chemical, biological and advanced therapy applications for all phases of study. He became Head of the Unit in 2015 and is currently involved in European Medicine Agency and UK projects to prepare for implementation of the new clinical trials Regulations.

Dr Jörg Täubel MD FFPM

CEO, Richmond PharmacologyDr Jörg Täubel is a medical practitioner and CEO of Richmond Pharmacology which he co-founded in 2001. He has worked in clinical pharmacology for over 25 years and during that time he has conducted more than 400 early phase studies in patients and healthy volunteers; usually in the capacity of Principal Investigator since 1995. His experience ranges from first time in man (FTIM) to proof of concept (POC) studies. He has extensive experience in cardiology, neurology, gastroenterology, ethnic bridging studies. His work currently focuses on providing expert advice in cardiac safety assessments and ethnic comparison studies. DrTäubel is an honorary fellow at St George's University and author of over 50 publications in scientific journals. He is currently researching the role of hyperglycaemia in relation to sudden cardiac death in Type I diabetic patients. He presented his research at numerous international meetings and workshops in Europe, US and Japan.

Dr Radivoj Arezina MD MSc

Research Director, Richmond PharmacologyDr Arezina is a founding director of Richmond Pharmacology and an MHRA-licensed Qualified Person (QP) with the overall responsibility for the IMP aspects of clinical trial conduct at this leading contract research organisation. He qualified in medicine in 1987 at the Medical School of the University of Zagreb, Croatia. Having spent one year in clinical medicine, most of his professional life thereafter has been in clinical research. To date, Dr Arezina has been co-investigator on over 200 clinical trials ranging from bioequivalence to first-into-human and covering different therapeutic areas including cardiovascular, gastrointestinal, CNS, pain, dermatology, endocrinology and urology. Dr Arezina also teaches modules on investigational medicinal products in clinical trials to undergraduate and postgraduate students at University College London (UCL). He is a member of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI, UK) and a fellow of the Royal Society of Medicine.

Dr Chris Brünger, MD

President and CEO, Chief Medical OfficerDr. Brünger has over 20 years of global drug development experience and held senior R&D positions for Schering AG and Pharmacia Corporation in Japan and Germany from 1989 to 2003, before founding IDEC. He is also a licensed physician in Germany and Japan. Dr. Brünger’s unique experience in Japanese clinical practice and medical research, and expertise in international drug development enable him to work with clients to develop effective solutions to integrating Japanese regulatory and marketing requirements into global development programs. He has prepared and managed over 50 PMDA consultations, and pioneered Japanese-Korean clinical co-development and studies in ethnic Japanese outside Japan.

Dr Boaz Mendzelevski, MD

President, Cardiac Safety ConsultantsDr Boaz Mendzelevski is a consultant cardiologist and President of Cardiac Safety Constants Ltd, a London UK based consulting group that advises the pharmaceutical and biotechnology industry on cardiovascular safety and efficacy issues. Dr Mendzelevski received his MD degree from the Ben-Gurion University Medical School in Beer-Sheva, Israel. He completed full training in Internal Medicine and in Cardiology - and is a Board Certified Expert in both Internal Medicine and Cardiology. Dr Mendzelevski completed a further sub-speciality training in Interventional Cardiology and Cardiac Electrophysiology at the Royal Brompton Hospital in London, UK.

Neelam Patel, Interim Chief Executive Officer

MedCityMedCity is an enabler, positioning the greater south east of England as a gateway to the UK for life sciences research, development, manufacturing and commercialization. The organisation plays a pivotal role in bridging industry, NHS and academia.Neelam’s significant experience, has included private and public sector and not-for-profit. She has held a number of leadership roles with the pharmaceutical industry and sat on industry research committees at the Association of British Pharmaceutical Industries and has represented industry on a European Innovative Medicines Initiative exploring the linkage of electronic health records for research. Neelam also sits on the steering group for the NICE evaluation pilot of digital health technologies and the Public Health England evaluation advisory group.

To confirm your attendance please RSVP

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more